ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2197

Diagnostic Value of Blood B-Cell Subset Profiling and Autoimmunity Markers in Anti-SSA-Negative Sjögren’s Syndrome Patients

Divi Cornec1, Alain Saraux2, Jacques-Olivier Pers3, Sandrine Jousse-Joulin4, Yves Renaudineau3, Thierry Marhadour5 and Valerie Devauchelle-Pensec6, 1Department of rheumatology, Brest Occidentale University, Brest, France, 2Department of rheumatology and unit of immunology (EA 2216), Brest Occidentale university, Brest, France, 3Unit of immunology, EA 2216, Brest Occidentale University, Brest, France, 4Rheumatology/Immunology, CHU de la Cavale Blanche, Brest, France, 5Rheumatology, CHU de la Cavale Blanche, Brest, France, 6Department of rheumatology and unit of immunology (EA2216), Brest Occidentale university, Brest, France

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: autoantibodies and diagnostic criteria, B cells, Sjogren's syndrome

  • Tweet
  • Email
  • Print
Session Information

Title: Sjögren's Syndrome - Clinical

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Recently published ACR classification criteria for primary Sjögren’s syndrome (pSS) suggest considering antinuclear antibodies (ANA) titer and rheumatoid factor (RF) positivity in patients negative for anti-Ro/SSA antibodies. The diagnostic value of these tests for pSS has to be confirmed in independant cohorts. Besides, we have shown in a previous case-control study that blood B-cell subset profiling through (Bm2+Bm2’)/(eBm5+Bm5) ratio computation is abnormal in pSS patients. Gammaglobulins and IgG titers are often increased in these patients. The aim of this study was to evaluate the diagnostic value of these B-cell markers for pSS, and to assess if they could improve American-European Consensus Group (AECG) criteria.

Methods:

This cross-sectional study was conducted in a monocentric cohort of patients with suspected pSS, prospectively included between November 2006 and September 2011. Clinical examination, basic biology, immunological tests and minor labial salivary gland biopsy (SGB) were performed systematically. For blood B-cell subset profiling, the (Bm2+Bm2’)/(eBm5+Bm5) ratio (referred to as B-cell ratio) was determined using flow cytometry. The gold standard for the analysis was a clinical diagnosis of pSS performed by a group of experts, blinded to the results of B-cell profiling. The diagnostic values and the independance of the different tests were compared using logistic regression analysis.

Results:

181 patients have been included in the study (mean age 56±13 years, symptoms duration 6.0±6.9 years, 92.2% females). 77 patients had pSS diagnosed by the experts. No differences were found between the 2 groups concerning age, disease duration, and sex ratio. The sensitivity (Se) and specificity (Sp) of the different tests were respectively: 60.6% and 99.0% for anti-SSA/SSB; 81.7% and 61.1% for ANA≥1:320; 70.4% and 83.2% for ANA≥1:640; 45.5% and 79.8% for IgM-RF; 42.3% and 97.9% for IgA-RF; 46.5% and 92.6% for gammaglobulins ≥14 g/l; and 49.6% and 91.6% for IgG ≥14 g/l. The mean B-cell ratio was significantly higher in the pSS group than in the non-pSS group (7.4±6.9 vs 3.2±2.3, P<0.001), and a ratio ≥5 had 52.1% Se and 83.2% Sp. Logistic regression analysis selected only ANA≥1:640 and B-cell ratio ≥5, with a similar weight. The combination of these two tests (ANA and ratio) displayed 37.7% Se and 96.2% Sp in the whole population, but only 12.9% Se in anti-SSA-negative patients. The association of the two tests (ANA or ratio) displayed 85.7% Se and 67.3% Sp in the whole group, and 71.0% Se in anti-SSA-negative patients. The modification of AECG criteria including the two tests in association (ANA or ratio) increased the Se from 83.1% to 90.9%, but decreased the Sp from 97.1% to 85.6%, whereas using the tests in combination (ANA and ratio) did not modify significantly their diagnostic value.

Conclusion:

Blood B-cell subset profiling using flow cytometry is a simple test which has good diagnostic properties for pSS.  However, the inclusion of this test, associated or not with ANA positivity, does not improve current classification criteria. Anti-SSA/SSB antibodies remain the best serologic item for the diagnosis of pSS.


Disclosure:

D. Cornec,
None;

A. Saraux,
None;

J. O. Pers,
None;

S. Jousse-Joulin,
None;

Y. Renaudineau,
None;

T. Marhadour,
None;

V. Devauchelle-Pensec,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/diagnostic-value-of-blood-b-cell-subset-profiling-and-autoimmunity-markers-in-anti-ssa-negative-sjogrens-syndrome-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology